ChinaTalk Chinese Peptides (Reported Podcast Special Edition!)
39 snips
Feb 13, 2026 
Aaron Kesselheim, Harvard physician and FDA policy expert, and Hamilton Morris, science journalist and chemist, dive into the world of Chinese peptides. They explore undercover sourcing, gray-market chemistry, regulatory gaps, industrial manufacturing in China, biohacking trends like BPC-157, and the tangled debate over enforcement versus access.
AI Snips
Chapters
Transcript
Episode notes
Undercover On Xiaohongshu Revealed Fast Responses
- Irene Zhang went undercover on Xiaohongshu and followed ten peptide factory accounts; all followed back within a day.
- Vendors quickly pushed WhatsApp, showed production videos, and claimed 10-day U.S. shipping with a 10-vial minimum.
Gray Market Undercuts Legit Drug Prices
- Chinese suppliers sell FDA-approved GLP-1 analogs like tirzepatide at tiny fractions of U.S. retail price.
- They also offer larger vials and unregulated dosages that raise safety concerns.
Individuals Claim Dramatic Recoveries With BPC-157
- Marcus and David used BPC-157 for severe injuries and report dramatic recoveries, including regrowth and sensory return.
- Their stories highlight why desperate patients seek unregulated peptides despite limited evidence.